• Kestra Medical Technologies, Inc.

  Led · Debt Financing · Jul 2026

  Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions. The company reported strong commercial momentum and attractive unit economics, according to CEO Brian Webster, and plans to continue investing in growth strategies. The newly arranged term loan was used in part to retire a prior $45 million term loan and to cover fees and expenses. Kestra has access to staged tranches of capital that include funded and optional amounts, plus an acquisition-focused uncommitted tranche subject to lender consent. The financing structure includes interest-only payments for the first 48 months (with a possible 12-month extension tied to a revenue milestone) and interest at SOFR plus 5.5% with a SOFR floor of 3.25%.

• BRAINBox Solutions

  Participated · Series A · Dec 2020

  BRAINBox Solutions is developing an AI-enabled, multi-modality approach to diagnose and prognose mild traumatic brain injury (concussion) that combines a proprietary panel of blood biomarkers with a digital neurocognitive testing platform to produce a composite TBI injury score. The company is working to deliver both point-of-care instruments and laboratory-based assays that can read the biomarker panel rapidly, and recently validated assay performance in a feasibility study on Prolight Diagnostics' Psyro/Pyros platform using 260 samples from its HeadSMART II pivotal trial. BRAINBox has entered a development agreement with Prolight to adapt that platform and plans to develop advanced hardware and software and acquire pilot instruments. The company intends to deploy its tests in hospital labs as well as clinics, ambulances, emergency departments, nursing homes, and athletic facilities. BRAINBox is led by physician and scientific thought leaders and an experienced clinically focused management team.

• PaxVax

  Led · Debt Financing · Jul 2014

  PaxVax is a fully integrated pharmaceutical company focused on development, manufacture and commercialization of innovative vaccines against infectious diseases. The company manufactures and markets Vivotif, an FDA‑approved oral typhoid vaccine licensed in 27 countries including the US and major European markets. It has vaccines in clinical development for cholera (Vaxchora), anthrax, HIV and hepatitis A. Led by CEO Nima Farzan, PaxVax operates R&D and GMP manufacturing facilities in San Diego, California and Bern, Switzerland. The company received a $105M investment in which an affiliate of Cerberus Capital Management acquired a majority economic interest. Cerberus has committed to support PaxVax’s specialty vaccine focus, R&D strategy and efforts to expand vaccine access in the developing world. PaxVax is a fully integrated specialty vaccine company whose portfolio includes a licensed oral typhoid vaccine (Vivotif®) and vaccine candidates for cholera (PXVX0200, in Phase 3), anthrax, HIV and H5N1, with research programs in malaria, dengue, rabies and HSV. The company acquired the FDA‑approved Vivotif product from Crucell Switzerland AG and has commenced commercial operations related to that acquisition. PaxVax is preparing for regulatory review and the anticipated global launch of its cholera vaccine candidate, PXVX0200. To support development and commercialization, PaxVax closed new financing and is supported by grants and contracts from NIH (NIAID, DAIDS, DMID), the Wellcome Trust and the Bill & Melinda Gates Foundation. The company previously has raised $80 million from equity investors including Ignition Ventures, Ignition Growth Capital and the Blue Haven Initiative. PaxVax was founded in 2007 and is headquartered in Redwood City, California, with R&D and GMP facilities in San Diego and a newly acquired facility near Bern, Switzerland. PaxVax develops and commercializes vaccines against infectious diseases using a proprietary adenoviral-based platform designed to enable rapid development of oral vaccines. Its lead candidate, PXVX0200 (CVD 103-HgR), is a single-dose oral cholera vaccine that has initiated a Phase 3 clinical program and has received Fast Track designation from the U.S. FDA. The Phase 3 program is an international pivotal study of approximately 3,000 participants, including cholera challenge, safety, and immunogenicity studies in the U.S., Australia, and Canada for use as a traveler’s vaccine. PaxVax’s pipeline also includes an H5N1 pandemic influenza vaccine entering Phase 2 and vaccines entering Phase 1 in HIV and anthrax under NIH contracts. The company highlights easier manufacture, storage, distribution, administration, and delivery of its oral candidates versus conventional injectables. PaxVax was founded in 2007 and is headquartered in Menlo Park, Calif., with R&D laboratories and a licensed GMP production facility in San Diego, Calif.

• Valneva

  Led · Debt Financing · Dec 2013

  Valneva is developing a Covid-19 vaccine named VLA2001. Its Scottish unit has received a $27 million grant from the Scottish government to fund R&D of manufacturing for VLA2001. The reported funding is described as a grant to support manufacturing research and development. The article does not provide timelines, production-capacity details, or operating metrics such as revenue or users. No other financings or investor participation are mentioned in the provided text. The item appears in a roundup and the fuller article is behind a sign-up prompt, limiting additional publicly available details. Valneva SE commercializes travel vaccines IXIARO/JESPECT (Japanese encephalitis) and DUKORAL (cholera/ETEC) and advances multiple vaccine candidates, including programs for Lyme disease and chikungunya. The company has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. and employs close to 500 people. Valneva completed Phase 2 patient recruitment for its Lyme program at the end of September and expects to report primary endpoint data mid‑2020. Management confirmed a mid‑term intention to list on Nasdaq, subject to shareholder approval, to co‑fund late‑stage development of the Lyme program. The company announced a debt financing to support advancement of its pipeline and to repay existing debt. Guggenheim Securities served as financial advisor and Dechert LLP as legal advisor in the transaction. Valneva develops and commercializes vaccines for infectious diseases with major unmet needs. Its commercial portfolio includes IXIARO/JESPECT for the prevention of Japanese encephalitis and DUKORAL for the prevention of cholera and, in some countries, ETEC-related diarrhea. The company has multiple vaccines in development, including unique candidates against Lyme disease and chikungunya. Valneva operates in Austria, Sweden, the United Kingdom, France, Canada and the US and has approximately 480 employees. The company announced a drawdown of €10 million from an existing European Investment Bank loan to support R&D and advance its clinical development-stage assets. Including this tranche, Valneva has drawn down €20 million of the €25 million facility and does not intend to draw the remaining €5 million. Valneva is a fully integrated, commercial-stage biotechnology company focused on developing and commercializing vaccines. The company markets two traveler vaccines: IXIARO®/JESPECT® for Japanese encephalitis and DUKORAL® for cholera and some ETEC-related diarrhea. Its proprietary pipeline includes candidates against Clostridium difficile and Lyme Borreliosis, and it leverages technology platforms such as the EB66® cell line and the IC31® adjuvant. Valneva pursues financial returns through focused R&D investments and growing contributions from its commercial products, aiming for financial self-sustainability. The company is listed on Euronext-Paris and the Vienna stock exchange and operates in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. Valneva is a fully integrated vaccine company focused on development, manufacture and commercialization of preventive vaccines. Its commercial portfolio includes two traveler vaccines: IXIARO/JESPECT for Japanese encephalitis and DUKORAL for cholera (and ETEC-related diarrhea in some countries). The company advances proprietary candidates including programs against Clostridium difficile and Lyme Borreliosis and leverages platforms such as the EB66 production cell line and the IC31 adjuvant. Valneva planned to enter its Lyme Borreliosis vaccine into Phase I in 2016 and is conducting preclinical R&D on a Zika vaccine candidate. Financially it is moving toward EBITDA break-even, intends to fund a substantial part of R&D from commercial product cash flows, and targets R&D spending of 15–20% of revenues. The company reports approximately 400 employees and is listed on Euronext Paris and the Vienna stock exchange.

No current team members are available.